Loading…
Biopharma with its own CNS drugs (Lybalvi for schizophrenia) plus royalties from partnered long-acting drug-delivery technology.
Biopharma with its own CNS drugs (Lybalvi for schizophrenia) plus royalties from partnered long-acting drug-delivery technology.
Earns from two sources: its own medicines, sold to psychiatrists and addiction clinics by a US sales force, and royalties and manufacturing fees from partners whose long-acting injectable drugs rely on its technology, such as Johnson & Johnson's. Own-product sales are the larger share, and royalty income costs little to earn and helps fund the pipeline.
Moat: narrow (IP / patents, process know-how). Proprietary long-acting and combination drug-delivery technology underlies both its own drugs and partner royalties.
Headquarters: Dublin, Ireland · Founded: 1987 · Employees: 2,050
Size Alkermes Public (ALKS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $7.71B, the 912th largest of 3,117 United States companies the cockpit tracks. Shares closed at $45.90 on 6 Nov 2026.
Performance Over six months the shares gained 31.2%, against +6.7% for the median peer and -1.1% for the United States market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 15.3% over the last twelve months (peer median +9.9%); the operating margin is 5.3% (peer median 16.9%).
Valuation It trades at 4.9× enterprise value to sales against a peer median of 4.6× (10th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +24 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.6 points below its cost of capital (6.3% WACC).
Short interest Short interest is 11.3% of the free float (15 Oct 2026).
Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.75B | $1.48B | $1.56B | $1.66B | $1.11B |
| Revenue growth | — | -5% | -6% | +50% | — |
| Gross profit | $1.39B | $1.27B | $1.31B | $1.37B | $847M |
| EBITDA | $173M | $281M | $449M | $489M | $71.8M |
| Net income | -$351,000 | $242M | $367M | $356M | -$158M |
| Free cash flow | $227M | $480M | $406M | $353M | -$17.2M |
| Capital expenditure | $15.6M | $40.4M | $33.5M | $48.0M | $38.3M |
| Total debt | $1.57B | $70.0M | $75.5M | $372M | $379M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Alkermes Public ALKS | $7.71B | +31% | +15% | 5% | 4.9× | 31.5% |
| Johnson & Johnson JNJ | $665B | +26% | +8% | 26% | 7.0× | 3.5% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.7B | +19% | -4% | 19% | 3.6× | 10.2% |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 3.2× | -12.9% |
| Indivior Pharmaceuticals INDV | n/a | -7% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALKS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.4% | +3.2% | 6th highest of 21 |
| 6-month return | +31.2% | +6.7% | 7th highest of 21 |
| Distance from 52-week high | -17.6% | -11.5% | 9th lowest of 21 |
| Revenue growth (TTM) | +15.3% | +9.9% | 9th highest of 20 |
| Operating margin | 5.3% | 16.9% | 4th lowest of 19 |
| EV / Sales | 4.9× | 4.6× | 10th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 31.5% | 7.2% | 2nd most demanding of 15 |
| Growth delivered (Del g) | +7.3% | +9.3% | 5th lowest of 15 |
| Hurdle (Req g minus delivered) | +24.2 pp | -6.5 pp | 2nd most demanding of 15 |
| ROIC minus cost of capital | -3.6 pp | +4.5 pp | 5th lowest of 20 |
| EV / EBITDA | 49.2× | 15.3× | 3rd most expensive of 12 |
| Net debt / EBITDA | 4.7× | -0.4× | 2nd most indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alkermes Public ALKS | United States | $7.71B | +31% | +15% | 5% | 4.9× | 31.5% | +7.3% |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.73B | +9% | +33% | 20% | 4.1× | 20.0% | +9.4% |
| Praxis Precision Medicines PRAX | United States | $7.75B | -16% | -100% | n/a | n/a | n/a | n/a |
| Rhythm Pharmaceuticals RYTM | United States | $7.78B | +19% | +61% | -67% | 27.4× | n/a | n/a |
| Grifols GRF.MC | Spain | $7.49B | +23% | 0% | 16% | 2.3× | 6.8% | +7.1% |
| Corcept Therapeutics CORT | United States | $7.96B | +39% | +30% | 12% | 7.9× | 24.9% | +16.6% |
| Cytokinetics CYTK | United States | $7.46B | -30% | -21% | -1,046% | 111.8× | n/a | n/a |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $8.02B | +47% | +9% | 27% | 2.4× | -9.1% | +6.6% |
| Kyowa Kirin 4151.T | Japan | $8.05B | +4% | +10% | 24% | 2.0× | -6.1% | +9.3% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.37B | +60% | +58% | 14% | 7.2× | 9.9% | +45.5% |
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $8.07B | +23% | +18% | 17% | 6.4× | n/a | n/a |
| Bachem BANB.SW | Switzerland | $7.32B | +3% | +5% | 19% | 8.7× | n/a | n/a |
| ALK-abello A/S ALK-B.CO | Denmark | $8.14B | -5% | +17% | 27% | 7.8× | 7.6% | +12.6% |
| Huadong Medicine 000963.SZ | China | $7.29B | -17% | +2% | 9% | 1.1× | -2.7% | +5.3% |
| Shanghai Pharmaceuticals 601607.SS | China | $8.32B | -2% | +4% | 3% | 0.3× | -10.0% | +8.1% |
| Amneal Pharmaceuticals AMRX | United States | $7.01B | +53% | +9% | 17% | 3.2× | 15.2% | +8.7% |
| ONO Pharmaceutical 4528.T | Japan | $7.01B | +2% | -2% | 22% | 2.0× | -8.2% | +10.8% |
| Protagonist Therapeutics PTGX | United States | $8.54B | +33% | +35% | 21% | 27.6× | 47.5% | +10.0% |
| RemeGen 9995.HK | Hong Kong | $6.92B | -31% | +293% | 61% | 5.1× | -4.8% | +57.9% |
| Shanghai Fosun Pharmaceutical (Group) 2196.HK | Hong Kong | $8.69B | -10% | +10% | 6% | 2.4× | 20.5% | +5.8% |
| Oruka Therapeutics ORKA | United States | $6.81B | +59% | n/a | n/a | n/a | n/a | n/a |